In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Molecular Partners brings in CHF46mm via its Series B round

Executive Summary

Molecular Partners AG (developing next-generation protein therapeutics) has raised CHF46mm ($45mm) through the closing of its Series B venture round. New investor Essex Woodlands Health Ventures led (and contributes a board member) and was joined by current backers Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures, and Endeavour.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies